make minor updat estim zoeti follow compani second-
quarter earn releas thursday morn august overal number
ahead estim full-year guidanc increas midpoint
though top-lin growth expect slow last quarter expect organ
growth come year hold steadi around includ faster growth
diagnost portfolio due abaxi acquisit well steadi innov
portfolio breadth across geographi speci
impress anoth strong perform quarter manag
team shown abil oper well mani type environmentsa
case point quarter headlin trade uncertainti transit strike brazil
worsen profit dairi farmer livestock busi still manag grow
organ believ stock upward move follow call reflect
investor relief compani abil consist perform well despit macro
condit move forward believ diagnost introduct newer
product intern market enabl compani grow slightli ahead
market rate maintain outperform rate zoeti given stabil
busi model prospect double-digit earn growth beyond
model overview despit guidanc rais maintain full year ep
target new midpoint manag guidanc rang increas
ep target penni reflect expect abaxi slightli
accret increas revenu target toward high end guidanc rang
calcul lesser neg impact foreign exchang million
discuss manag otherwis expect organ growth line
guidanc
return equiti ttm
zoeti leader develop manufactur market anim health medicin vaccin
product companion anim market annual revenu exceed billion compani found
divis spun februari oper countri maintain one
largest budget industri
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
innov manag commentari time combin flea-and-tick plu heartworm product
simparica trio appear conserv us believ product could receiv approv earli
europ though suspect earli reason timelin approv dermatolog portfolio
track well cytopoint expect reach blockbust statu year combin offer grow
year-over-year believ upsid dermatolog intern market note product
yet receiv approv china becom promin companion anim revenu sourc
compani livestock side newer product fostera gold appear boost compani organ
growth spite challeng condit produc global expect livestock expand
compar off-set companion anim slow last year previous
companion anim apoquel cytopoint combin million revenu second quarter
year-over-year increas see exhibit total impress million sequenti believ
part due time custom order flea tick season dermatolog sale reach million
million prior quarter manag note simparica reach million sale includ strong
initi uptak mexico product also well way blockbust statu despit late entrant
continu view simparica trio signific opportun growth beyond
exhibit quarterli apoquel cytopoint sale present
livestock livestock busi under-perform expect quarter growth compar
estim continu believ swine busi perform reason well despit trade fear
pcv product clear weak spot current dairi fulli convinc rebound
occur still view broader livestock market stabl overal view potenti diagnost
livestock space medium long term potenti add nice top-lin growth although
busi invest mode intern livestock busi exceed
expect manag note favor export condit brazil strong cattl perform australia
unit kingdom emerg market
increas revenu estim million billion includ
million beat second quarter versu model
million abaxi half-year contribut
million decreas foreign exchang previous updat estim foreign currenc
million decreas lower organ growth back half
expect unit state grow organ versu previous expect intern
segment increas compar previous four fewer sell day fourth quarter account
entireti chang model
decreas ebit margin assumpt basi point result abaxi acquisit
increas core sg spend lower full-year tax rate previous
aggreg leav ep estim unchang
increas revenu estim million billion includ full-
year contribut abaxi million includ revenu synergi increas ep estim
penni reflect penni estim accret abaxi deal
valuat stock thought
zoeti trade time updat ep estim compar post-ipo averag time
forward earn small-cap anim health peer time higher growth veterinari peer time
continu impress manag steadi execut result reiter outperform rate
despit expand valuat summari revis model found exhibit
good gross gener research amort intang total oper oper expense/ incom pre-tax tax net loss attribut non-controlling net incom excl non-recurring non-recurring item net net ep excl non-recurring per average share outstand margin analysi gross metric total revenu constant oper revenu constant incom excl non-recur excl non-recur share blair compani estimatesourc compani report william blair compani llc estim import disclosur
